ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Sino Biopharmaceutical Ltd. ?
1
High Management Efficiency with a high ROE of 94.58%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 32.34
3
Poor long term growth as Operating profit has grown by an annual rate 3.69% of over the last 5 years
4
Flat results in Dec 25
- NET PROFIT(Q) Lowest at HKD -154.86 MM
- EPS(Q) Lowest at HKD -0.06
5
With ROE of 36.44%, it has a Very Attractive valuation with a 3.13 Price to Book Value
- Over the past year, while the stock has generated a return of 23.99%, its profits have risen by 153.7% ; the PEG ratio of the company is 0.1
6
Market Beating Performance
- The stock has generated a return of 23.99% in the last 1 year, much higher than market (Hang Seng Hong Kong) returns of 8.76%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Sino Biopharmaceutical Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sino Biopharmaceutical Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Sino Biopharmaceutical Ltd.
23.99%
5.93
43.45%
Hang Seng Hong Kong
8.76%
0.45
19.63%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.51%
EBIT Growth (5y)
3.69%
EBIT to Interest (avg)
32.34
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.63
Tax Ratio
25.58%
Dividend Payout Ratio
70.82%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
134.35%
ROE (avg)
94.58%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
3.13
EV to EBIT
20.64
EV to EBITDA
15.93
EV to Capital Employed
3.80
EV to Sales
3.55
PEG Ratio
0.06
Dividend Yield
98.57%
ROCE (Latest)
18.39%
ROE (Latest)
36.44%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend2What is working for the Company
CASH AND EQV(HY)
Highest at HKD 25,574.81 MM
OPERATING PROFIT MARGIN(Q)
Highest at 27.12 %
-4What is not working for the Company
NET PROFIT(Q)
Lowest at HKD -154.86 MM
EPS(Q)
Lowest at HKD -0.06
Here's what is working for Sino Biopharmaceutical Ltd.
Operating Profit Margin
Highest at 27.12 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Cash and Eqv
Highest at HKD 25,574.81 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Depreciation
At HKD 680.87 MM has Grown at 12.84%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (HKD MM)
Here's what is not working for Sino Biopharmaceutical Ltd.
Net Profit
At HKD -154.86 MM has Fallen at -108.17%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (HKD MM)
Net Profit
Lowest at HKD -154.86 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (HKD MM)
EPS
Lowest at HKD -0.06
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (HKD)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
